Amneal Pharmaceuticals, Inc. AMRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.02B+8.0% | $2.79B+16.7% | $2.39B+8.2% | $2.21B+5.7% | ||
| $1.91B+7.4% | $1.77B+12.7% | $1.57B+10.2% | $1.43B+7.8% | ||
| $1.11B+9.1% | $1.02B+24.4% | $820.57M+4.6% | $784.71M+2.0% | ||
| 36.9%+0.4pp | 36.5%+2.2pp | 34.3%-1.2pp | 35.5%-1.3pp | ||
| $186.18M-2.4% | $190.71M+16.3% | $163.95M-16.2% | $195.69M-3.1% | ||
| $526.83M+10.6% | $476.44M+10.9% | $429.68M+7.5% | $399.7M+9.4% | ||
| —— | —— | —— | —— | ||
| $5.24M+463% | $930K-94.1% | $15.64M— | —— | ||
| $394.1M+58.1% | $249.33M+22.0% | $204.37M— | —— | ||
| 13.1%+4.1pp | 8.9%+0.4pp | 8.5%— | —— | ||
| -$241.09M+6.8% | -$258.6M-22.8% | -$210.63M-33.0% | -$158.38M-16.2% | ||
| -$254.89M+16.2% | -$304.34M-24.4% | -$244.64M-59.7% | -$153.2M-26.2% | ||
| —— | —— | -$40.81M-13,922% | -$291K— | ||
| $139.21M+353% | -$55.01M-36.6% | -$40.27M+83.8% | -$248.13M— | ||
| $11.28M-40.2% | $18.86M+123% | $8.45M— | —— | ||
| $72.06M+162% | -$116.89M-39.2% | -$83.99M+67.0% | -$254.79M— | ||
| 2.4%+6.6pp | -4.2%-0.7pp | -3.5%+8.0pp | -11.5%— | ||
| $0.23+161% | -$0.38+20.8% | -$0.48+44.2% | -$0.86— | ||
| $0.23+161% | -$0.38+22.4% | -$0.49+43.0% | -$0.86— | ||
| 1.3B+4.1% | 1.2B+93.7% | 642.8M+6.6% | 603.2M-0.2% | ||
| 1.3B+1.4% | 1.2B+94.1% | 636.2M+5.5% | 603.2M+1.3% | ||
| $390K+100% | -$96.69M-5,201% | -$1.82M+99.3% | -$269.93M-980% | ||
| -$6.59M+87.0% | -$50.68M-1,522% | -$3.12M-395% | -$631K— | ||
| -$241.09M+6.8% | -$258.6M-22.8% | -$210.63M-33.0% | -$158.38M-16.2% | ||
| —— | -$6.85M-510% | $1.67M+113% | -$12.93M-3,543% | ||
| $7.63M+30.6% | $5.85M+52.7% | $3.83M-12.2% | $4.36M— | ||
| $16.52M+40.2% | $11.78M+42.9% | $8.24M-55.4% | $18.46M+20.4% | ||
| $5.24M+463% | $930K-94.1% | $15.64M— | —— | ||
| $3.02B+8.0% | $2.79B+16.7% | $2.39B+8.2% | $2.21B+5.7% | ||
| $394.1M+58.1% | $249.33M+22.0% | $204.37M+210% | -$185.64M-222% | ||
| $394.1M+58.1% | $249.33M+22.0% | $204.37M+210% | -$185.64M-222% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $3.0B in revenue over the trailing twelve months, up 7.6% year over year.
- Is Amneal Pharmaceuticals, Inc. profitable?
- Amneal Pharmaceuticals, Inc. reported $122.1M in net income over the trailing twelve months, a 4.0% net margin.
- What are Amneal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 38.7% and operating margin is 14.3%, with a 4.0% net margin.
- What is Amneal Pharmaceuticals, Inc.'s earnings per share?
- Amneal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $0.38.
- Where does Amneal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
